Sex: M
Vaccine: COVID19, COVID19
Symptoms: Atrial thrombosis, Dizziness, Peripheral artery thrombosis
Clinical narrative: left radial artery left arm blood clot; Left radial artery left arm blood clot; Dizzy; This spontaneous case was reported by a consumer and describes the occurrence of ATRIAL THROMBOSIS (left radial artery left arm blood clot) and PERIPHERAL ARTERY THROMBOSIS (Left radial artery left arm blood clot) in an adult male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination and ADALIMUMAB (HUMIRA) solution for injection for Hidradenitis suppurativa.    Concurrent medical conditions included Hidradenitis suppurativa.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form, third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) CF. On an unknown date, the patient experienced ATRIAL THROMBOSIS (left radial artery left arm blood clot) (seriousness criterion medically significant), PERIPHERAL ARTERY THROMBOSIS (Left radial artery left arm blood clot) (seriousness criterion medically significant) and DIZZINESS (Dizzy). At the time of the report, ATRIAL THROMBOSIS (left radial artery left arm blood clot) was resolving and PERIPHERAL ARTERY THROMBOSIS (Left radial artery left arm blood clot) and DIZZINESS (Dizzy) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medication information was provided. Patient was waking up in mornings and dizzy. It was unknown if patient was  enrolled in a COVID-19 Vaccine Trial. No treatment medications were provided.  Company comment: This is a spontaneous case concerning a 50-year-old male patient with  medical history of hidradenitis suppurativa receiving Adalimumab, who experienced the serious (medically significant) unexpected events atrial thrombosis and arterial thrombosis of the arm, on an unknown date after receiving an unspecified dose of mRNA-1273. Clinical course, diagnostic tests and treatment details were not provided. Pfizer Biontech COVID-19 vaccine Tozineram and concomitant Adalimumab (Humira) were also reported as suspect drugs.  Further information has been request. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: Company comment: This is a spontaneous case concerning a 50-year-old male patient with  medical history of hidradenitis suppurativa receiving Adalimumab, who experienced the serious (medically significant) unexpected events atrial thrombosis and arterial thrombosis of the arm, on an unknown date after receiving an unspecified dose of mRNA-1273. Clinical course, diagnostic tests and treatment details were not provided. Pfizer Biontech COVID-19 vaccine Tozineram and concomitant Adalimumab (Humira) were also reported as suspect drugs. Further information has been request. The benefit-risk relationship of mRNA-1273 is not affected by this report.